Informations

Immune thrombocytopenia (ITP) is a common autoimmune bleeding disorder characterized by accelerated platelet destruction and impaired platelet production due to antibody-mediated mechanisms. Current first-line therapies for ITP include glucocorticoids and immunoglobulins, while second-line options often involve thrombopoietin receptor agonists (TPO-RAs), CD20 monoclonal antibodies, and splenectomy. The introduction of CD20 monoclonal antibody therapy over the past…

Recently, the team led by Professor Junren Chen from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, along with Professor Zimin Sun’s team from The First Affiliated Hospital of the University of Science and Technology of China, conducted a retrospective analysis of 620 unrelated cord blood transplant cases in Anhui.

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore…